Advances in analgesic drug design and delivery: A current survey

Advances in Experimental Medicine and Biology

Volumn 553, Issue , 2004, Pages 209-219

  Bonney, Iwona Maszczynska ^a   Keskin, Dilek Sendil ^b   Lipkowski, Andrzej W ^c   Hasirci, Vasif ^b   Carr, Daniel B ^a  

^a TUFTS MEDICAL CENTER   (United States)

^b MIDDLE EAST TECHNICAL UNIVERSITY   (Turkey)

^c MOSSAKOWSKI MEDICAL RESEARCH CENTRE   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

AA 501; ANALGESIC AGENT; BENZOCAINE; BIPHALIN; BUPIVACAINE; CINCHOCAINE; CODEINE; DEXAMETHASONE; ESP 7; HYDROMORPHONE; LIDOCAINE; LOCAL ANESTHETIC AGENT; MICROSPHERE; MORPHINE; NEW DRUG; OPIATE; POLYGLACTIN; POLYLACTIC ACID; POLYMER; SUBSTANCE P DERIVATIVE; UNCLASSIFIED DRUG;

ANALGESIA; ANALGESIC ACTIVITY; BIOCOMPATIBILITY; BIODEGRADABILITY; BIODEGRADABLE IMPLANT; CONFERENCE PAPER; CONTROLLED RELEASE FORMULATION; DEVICE; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG EFFICACY; DRUG IMPLANT; DRUG RECEPTOR BINDING; DRUG RELEASE; DRUG STRUCTURE; DRUG TARGETING; HUMAN; MICROCAPSULE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR AFFINITY; TECHNIQUE;

EID: 6344292308     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-0-306-48584-8_16     Document Type: Conference Paper

References (41)

1. Merskey, H., and Bogduk, N., 1994, Classification of Chronic Pain, Second Edition, IASP Task Force on Taxonomy (Merskey, H., and Bogduk, N., eds.), IASP Press, Seattle, pp. 209-214.
2. Harstall, C., and Ospina, M., 2003, How prevalent is chronic pain? Pain: Clinical Updates Vol. XI, No.2.
3. Verhaak, P.F.M., Kerssens, J.J., Dekker, J., Sorbi, M.J., Bensing, J.M., 1998, Prevalence of chronic benign pain disorder among adults: a review of the literature. Pain 77: 231-239.
4. Kloke, M., Rapp, M., Bosse, B., Kloke, O., 2000, Toxicity and/or insufficient analgesia by opioid therapy: risk factors and the impact of changing the opioid. A retrospective analysis of 273 patients observed at a single center. Supportive Care in Cancer 8: 479-486.
5. Goudas, L.C., Carr, D.B., Bloch, R., Balk, E., Ioannidis, J.P.A., Terrin, N., Gialeli-Goudas, M., Chew, P., Lau, J., October 2001, Management of cancer pain. Volume 1 and 2. Evidence Report/Technology Assessment No. 35, Agency for Healthcare Research and Quality (AHRQ) Publication No. 02-E002.
6. Carr, D.B., Goudas, L.C., Lawrence, D., Pirl, W., Lau, J., DeVine, D., Kupelnick, B., Miller, K., July 2002, Management of cancer symptoms: pain, depression, and fatigue. Evidence Report/Technology Assessment No. 61, Agency for Healthcare Research and Quality (AHRQ) Publication No. 02-E032.
7. Renck, H., and Wallin, R., 1996, Slow release formulations of local anesthetics and opioids. Current Opinion in Anesthesiology 9: 399-403.
8. Hasirci, V., Sendil, D., Goudas, L.C., Carr, D.B., Wise, D.L., 2000, Controlled release pain management systems. In: Handbook of pharmaceutical controlled release technology (Wise D.L., ed.), Marcel Dekker, Inc., New York, Basel, pp. 787-806.
9. Carr, D.B., and Sendil, D., 2002, Current approaches to analgesic drug delivery for chronic pain. Technology & Health Care 10: 227-235.
10. Sackler, R., Goldenheim, P., Chasin, M., 1998, Prolonged local anesthesia with colchicine, US Patent 5,747,060.
11. Le Corre, P., Rytting, J.H., Gajan, V., Chevanne, F., Le Verge, R., 1997, In vitro controlled release kinetics of local anesthetics from poly(D,L-lactide) and poly(lactide-co-glycolide) microspheres. J Microencapsul 14: 243-255.
12. Wakiyama, N., Juni, K., Nakano, M., 1981, Preparation and evaluation in vitro of poly lactic acid microspheres containing local anesthetics. Chem Pharm Bull 29: 3363-3368.
13. Wakiyama, N., Juni, K., Nakano, M., 1982, Influence of physicochemical properties of polylactic acid on the characteristics and in vitro release patterns of polylactic acid microspheres containing local anesthetics. Chem Pharm Bull 30: 2621-2628.
14. Curley, J., Castillo, J., Hotz, J., Uezono, M., Hernandez, S., Lim, J-O., Tigner, J., Chasin, M., 1996, Prolonged regional nerve blockade. Injectable biodegradable bupivacaine/polyester microspheres. Anesthesiology 84: 1401-1410.
15. Malinovsky, J.M., Bernard, J.M., Le Corre, P., Dumand, J.B., Lepage, J.Y., Le Verge, R., Souron, R., 1995, Motor and blood pressure effects of epidural sustained-release bupivacaine from polymer microspheres: a dose-response study in rabbits. Anesth Analg 81: 519-524.
16. Soo Choi, H., Seo, S.A., Khang, G., Rhee, J.M., Lee, H.B., 2002, Preparation and characterization of fentanyl-loaded PLGA microspheres: in vitro release profiles. International Journal of Pharmaceutics 234: 195-203.
17. Kojima, T., Nakano, M., Juni, K., Inoue, S., Yoshida, Y., 1984, Preparation and evaluation in vitro of polycarbonate microspheres containing local anesthetics. Chem Pharm Bull 32: 2795-2802.
18. Grossman, S.A., Leong, K.W., Lesser, G.J., Lo, H., 1997, Subcutaneous Implant, US Patent 5,633,000.
19. Sendil, D., Wise, D.L., Hasirci, V., 2002, Assessment of biodegradable controlled release rod systems for pain relief applications. J. Biomat. Sci. Polym. Ed. 13: 1-15.
20. Hasirci, V., Bonney, I., Goudas, L.C., Sinister, L., Carr, D.B., Wise, D.L., 2003, Antihyperalgesic effect of simultaneously released hydromorphone and bupivacaine from polymer fibers in the rat chronic constriction injury model. Life Sci 73: 3323-3337.
21. Sendil Keskin, D., Altunay, H., Wise, D.L., Hasirci, V., 2003, In vivo pain relief effectiveness of analgesic-anesthetic carrying biodegradable controlled release rod systems. J. Biomaterials Sciences, Polymer Edition, in press.
22. Sendil, D., Maszczynska Bonney, I., Carr, D.B., Lipkowski, A.W., Wise, D.L., Hasirci, V., 2003, Antinociceptive effects of hydromorphone, bupivacaine and biphalin released from PLGA polymer after intrathecal implantation in rats. Biomaterials 24: 1969-1976.
23. rd Ed., Lippincott-Raven Publishing, pp. 915-983.
24. Walker, S., Goudas, L.C., Cousins, M.J., Carr, D.B., 2002, Combination spinal analgesic chemotherapy: a systematic review. Anesthesia Analgesia 95: 674-715.
25. Kosson, D., Lachwa, M., Maszczynska, I., Misicka, A., Carr, D.B., Lipkowski, A.W., 1999, Potential application of peptides as the new generation analgesics. Anestezjologia Intensywna Terapia 31 (Suppl. II): 55-56.
26. Lipkowski, A.W., Konecka, A.M., Sroczynska, I., 1982, Double-enkephalins-synthesis, activity on guinea-pig ileum, and analgesic effect. Peptides 3: 697-700.
27. Lipkowski, A.W., Konecka, A.M., Sroczynska, I., Przewlocki, R., Stala, L, Tam, S.W., 1987, Bivalent opioid peptide analogues with reduced distances between pharmacophores. Life Sci., 40, 2283-2288.
28. Flippen-Anderson, J.L., Deschamps, J.R., George, C, Hruby, V.J., Misicka, A., Lipkowski, A.W., 2002, Crystal structure of biphalin sulfate: a multireceptor opioid peptide. J. Peptide Res. 59, 123-133.
29. Lipkowski, A.W., Carr, D.B., Bonney, I., Misicka, A., Payza K., 2003, Biphalin: A Multireceptor Opioid Ligand Binding and Activity of Opioid Ligands at the Cloned Human Delta, Mu, and Kappa Receptors. In The Delta Receptor. (Chang, K-J., Porreca, F., and Woods, J.H., eds.), Marcel Dekker, Inc., New York, in press.
30. Horan, P.J., Mattia, A., Bilsky, E., Weber, S., Davis, T.P., Yamamura, H.I., Malatynska, E, Appleyard, S.M., Slaninova, J, Misicka, A., Lipkowski, A.W., Hruby, V.J., Porreca F., 1993, Antinociceptive profile of biphalin, a dimeric enkephalin analog. J. Exp. Pharm. Ther. 265: 1446-1454.
31. Yamazaki, M., Suzuki, T., Narita, M., Lipkowski, A.W., 2001, The opioid peptide analogue biphalin induces less physical dependence than morphine. Life Sci. 69, 1023-1028.
32. Misterek, K., Maszczynska, I., Dorociak, A., Gumulka, S.W., Carr, D.B., Szyfelbein, S.K., Lipkowski, A.W., 1994, Spinal co-administration of peptide substance P antagonist increases antinociceptive effect of the opioid peptide biphalin. Life Sci. 54, 936-944.
33. Lipkowski A.W., Carr D.B., Misicka A., Misterek K., 1994, Biological activities of peptide containing both casomorphine-like and substance P antagonist structural characteristics. In β-Casomorphins and related peptides: Recent developments (Brantl, V., Teschemacher, H., eds.), VCH, Weinheim, pp. 113-118.
34. Maszczynska Bonney, I., Foran, S.E., Marchand, J.E, Lipkowski, A.W., Carr, D.B., 2004, Spinal antinociceptive effects of AA501, a novel chimeric peptide with opioid agonist and neurokinin antagonist moieties. Eur. J. Pharmacol, in press.
35. Lipkowski, A.W., Osipiak, B., Czlonkowski, A., Gumulka, W.S., 1982, An approach to the elucidation of self-regulatory mechanism of substance P action. I. Synthesis and biological properties of pentapeptides related both to the substance P C-terminal fragment and enkephalins. Polish J. Pharmacol. Pharm. 34, 63-68.
36. Klusha, V.E., Abissova, N.A., Muceniece, R.K., Svirskis, S.V., Bienert, M., Lipkowski, A.W., 1981, Comparative study of substance P and its fragments: analgesic properties, effect on behavior and monoaminergic processes. Bull. Exp. Biol. Med. Eng. Tr., 92, 1665-1667.
37. Maszczynska, I., Lipkowski, A.W., Carr, D.B., Kream, R.M., 1998, Dual functional interactions of substance P and opioids in nociceptive transmission: review and reconciliation. Analgesia 3: 259-268.
38. Kream, R.M., Kato, T., Shimonaka, H., Marchand, J.E., Wurm, W.H., 1993, Substance P markedly potentiates the antinociceptive effects of morphine sulfate administered at the spinal level. Proc. Natl. Acad. Sci. USA 90, 3564-3568.
39. Lipkowski, A.W., Osipiak, B., Gumulka, W.S., 1983, An approach to the self regulatory mechanism of substance P actions: II. Biological activity of new synthetic peptide analogs related both to enkephalin and substance P. Life Sci. 33 (Suppl. I.). 141-144.
40. Lei, S.Z., Lipkowski, A.W., Wilcox, G.L., 1991, Opioid and neurokinin activities of substance P fragments and their analogs. Eur. J. Pharmacol. 193, 209-215.
41. Foran, S.E., Carr, D.B., Lipkowski, A.W., Maszczynska, I., Marchand, J.E., Misicka, A., Beinborn, M., Kopin, A., Kream, R.M., 2000, A substance P-opioid chimeric peptide as a unique nontolerance-forming analgesic. Proc. Natl. Acad. Sci. USA, 97, 7621-7626.